Illumina inks deal with J&J, AstraZeneca, Sanofi

Share this article:

Illumina has teamed up with three drugmakers in an effort to create diagnostics which will help match patients to the right cancer treatments. The collaboration will use Illumina's rapid sequencing technology, and the goal is to create a diagnostic that will be of use to patients and which will also be used as part of a drugmaker's clinical trials.

Forbes's Matthew Herper points out that such diagnostics are essential because they help eliminate drugs that are not worth a patient's time or expense as well as point to drug combinations that could make a difference. llumina's chief medical officer told Herper in an earlier interview that the firm's goal is to create a universal testing panel. He said part of this goal requires a willingness to collaborate, with drugmakers sharing what genes their drugs are targeting.

“Our aim is for doctors to be able to use these tests to prescribe the right medicines for the right patients—bringing benefits to healthcare professionals, payers and patients alike,” AstraZeneca's personalized healthcare and biomarkers VP Ruth March said in a statement.

Friends of Cancer Research Ellen Sigal considers the effort a watershed moment. "The transition to patient-centered companion therapeutics marks a new era for oncology," she said in a statement published by Illumina.

The new test will focus on around 125 cancer-causing genes.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.